PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Abroad (travel likely)RecruitingPHASE2
Conditions
Breast Neoplasm · Triple Negative Breast Cancer (TNBC) · HRD
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
King's College Hospital, London, England, United Kingdom
Contact: Principal Investigator (Dr Castell)Christie Hospital NHS Trust, Manchester, England, United Kingdom
Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom
Contact: Principal Investigator (Dr Borley)Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Dr Irshad)Weston Park Hospital, Sheffield, United Kingdom
Study leads
Andrew Tutt
Principal Investigator
Institute of Cancer Research, United Kingdom